IndustryCompany release

Anaptys reports quarterly results as Jemperli sales rise 29% and GSK dispute ruling nears

🇺🇸 Anaptysbio, Inc (ANAB) · Thu 12 Nov 2026

Anaptys posted $30.3 million in collaboration revenue for the September quarter, with a rectal cancer approval for Jemperli and a Delaware judgment and an FDA decision both approaching.

Anaptys reported results for the quarter ended 30 September 2026 on 12 November. Collaboration revenue for the period was $30.3 million.

Global net sales of Jemperli (dostarlimab) reached $1.0 billion over the first nine months, an increase of 29%. Jemperli is the product at the centre of Anaptys's royalty-linked interest and of its dispute with GSK.

In October 2026 the US Food and Drug Administration approved Jemperli for locally advanced rectal cancer at stage II or III that is MSI-H or dMMR, meaning the tumours show high microsatellite instability or deficient mismatch repair.

Anaptys said it expects a judgment from the Delaware Chancery Court in the dispute involving GSK and Tesaro in either the fourth quarter of 2026 or the first quarter of 2027.

A further regulatory milestone is due on 12 December 2026, the FDA decision date for Vanda's Quimilza (imsidolimab) in generalised pustular psoriasis.

What it means for your team

  • Regulatory teams should note the October FDA approval of Jemperli in MSI-H/dMMR stage II/III locally advanced rectal cancer, which widens its US use in a biomarker-defined population.
  • Market-access teams tracking Jemperli should factor in the 29% nine-month sales growth and the new rectal cancer indication.
  • The 12 December 2026 FDA decision date for Quimilza in generalised pustular psoriasis is a near-term event to watch in rare inflammatory skin disease.
  • The Delaware Chancery Court judgment in the GSK/Tesaro dispute is expected in Q4 2026 or Q1 2027 and could affect the commercial terms around Jemperli.

Company's press release (SEC filing): Anaptysbio, Inc ↗

Article written by VigiEye from the official source (Anaptysbio, Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →